





































Serum growth factors (GF) activate the GF-sensing 
network, which turns on both cell cycle progression and 
the mTOR pathway, which in turn stimulates cellular 
growth in size [1-5]. While growing in size, cells 
progress through the cell cycle and divide. Thus, in 
proliferating cells, cellular growth is balanced with cell 
division.  
 
In normal cells, serum withdrawal both arrests the cell 
cycle early in G1, also known as G0 and deactivates 
mTOR.  Cells become quiescent: they neither grow in 
size nor progress through the cell cycle. In contrast, 
cellular senescence is characterized by cellular 
hypertrophy (large and flat cell morphology), 
hypersecretory phenotype, beta-Gal-staining and perma- 
 
 




































nent loss of proliferative potential [6-8]. Cellular 
senescence is not caused by serum GF withdrawal, but 
by stresses and oncogenic/mitogenic hyper-stimulation 
[9-15]. While not inhibiting mTOR, these stimuli incite 
responses blocking cell cycle. 
 
In theory, if the cell cycle is blocked, while serum 
continues to activate GF-sensing pathways, cells will 
senesce [16, 17]. For example, p21 causes cell cycle 
arrest without inhibiting mTOR, and thus causes senes-
cence. Deactivation of mTOR by rapamycin prevented 
p21-induced senescence, converting p21-induced arrest 
into quiescence [18-20].  
 
The tumor suppressor p53 inhibits the mTOR pathway 
upstream [21-24] and downstream [25, 26] of mTOR. 
While inhibiting mTOR, p53 suppressed p21-induced 
DNA damaging agents and p53 do not cause senescence in quiescent 
cells, while consecutive re-activation of mTOR is associated with 
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affects autophagy and metabolic pathways not only via 
inhibition of mTOR but also probably independently 
from mTOR [22,28-35]. We use the term mTOR-
centric network to encompass not only upstream and 
downstream but also parallel and TOR-like pathways 
[36].  
 
p53 can both induce and suppress cellular senescence 
[37]. First, p53 causes cell cycle arrest, a prerequisite of 
senescence. Second, p53 inhibits mTOR-centric 
network and this can prevent senescence, causing 
quiescence instead. In cell lines with overactivated 
mTOR, p53 causes senescence [37]. Similarly, “weak” 
p53 that is not able to inhibit mTOR causes senescence 
simply by arresting the cell cycle [38]. In other words, 
p53 causes senescence passively by failing to suppress 
the senescence program (which in part depends on 
mTOR), while still causing cell cycle arrest. This model 
suggests that cell cycle arrest is the only mechanism of 
how p53 causes senescence. This predicts that induction 
of p53 will not cause senescence in quiescent cells, 
since in quiescent cells mTOR is already inhibited. Here 































Induction of p53 by etoposide in quiescent cells has 
little consequence 
 
As we recently demonstrated, unlike nutlin-3a (an 
Mdm-2 antagonist), low concentrations of doxorubicin 
(DOX), a DNA damaging drug (DDD), caused 
senescent morphology in WI-38t cells [38]. Nutlin-3a 
causes cell cycle arrest solely by inducing p53, which in 
turn can inhibit the mTOR pathway. DOX causes cell 
cycle arrest at concentrations that induce p53 not high 
enough to inhibit mTOR. Therefore, DOX caused 
senescence as was determined by senescent morphology 
[38]. However, DOX is not washable and we could not 
check whether the condition was irreversible. Here we 
used etoposide, a DDD that could be washed out. We 
treated WI-38t cells with either etoposide or nutlin-3a. 
After 4 days, cells were washed and re-plated without 
drugs (Figure 1A). After 6 days, the number of nutlin-
treated cells increased ~26 fold, whereas etoposide-
treated cells could not proliferate (Figure 1A).  In 
parallel, cells were treated with nutlin-3a and etoposide 
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etoposide-treated cells. Direct comparison of the 
proliferative potential of WI-38t cells treated with 
etoposide in the absence or presence of rapamycin is 
shown in Figure 1C.   Etoposide did not inhibit mTOR 
and inhibition of mTOR by rapamycin-pretreatment 
(Figure 1D) favored quiescence over senescence (Figure 
1C).   
 
We further investigated effects of etoposide in cells 
treated by either rapamycin or serum starvation as 
depicted in Figure 2.  Exposure of WI-38t cells to either 
rapamycin or serum starvation resulted in a lean cellular 
morphology, a characteristic of quiescence (Figure 3A, 
left column). Treatment of proliferating WI-38t cells 
with etoposide caused senescent morphology (Figure 
3A, top right panel). Senescent morphology was 
partially preventable by rapamycin and serum-
starvation:  most cells were lean and thin (Figure 3A, 
right column). Rapamycin did not inhibit proliferation 





































































p53  in  proliferating  versus  quiescent  cells.  Cells  are 
treated (or left untreated) under different condi‐tions [control 
(10% serum), 0% serum or rapamycin] with etoposide for 4 
days.  Cells  are  counted  twice:  1)  at  the  time  of  etoposide 
removal  to  measure  inhibition  of  proliferation  and  2)  6‐11 
days  after  wash  to  measure  proliferative  potential  (PP).  PP 
should not be confused with proliferation. Thus, rapamycin 























































agreement with similar experiment (Figure 1C), 
rapamycin partially prevented loss of proliferative 
potential caused by etoposide (Figure 3C). Serum 
starvation preserved proliferative potential (PP) in 
etoposide-treated cells (Figure 3C).   Etoposide  induced 
p53 in serum-starved cells even stronger than in control 
(proliferating) cells (Figure 3D). So the failure to 
initiate senescence could not be explained by lack of 
p53 induction. 
 
We next investigated etoposide-induced senescence in 
normal retinal pigment epithelial (RPE) cells. Etoposide 
caused senescent morphology in RPE cells (Figure 4A). 
Pretreatment with rapamycin and serum-starvation 
partially prevented senescent morphology caused by 
etoposide. The senescent morphology was associ-         







































could not resume proliferation, when etoposide was 
removed (Figure 4B, C). In rapamycin-pretreated cells 
and, especially, in serum-starved cells, etoposide-
induced arrest was partially reversible. Both rapamycin 
and serum starvation inactivated the mTOR pathway, as  
measured by a decrease of S6 phosphorylation (Figure 
4D), but did not prevent p53 and p21 induction by 
etoposide (Figure 4D). Noteworthy, rapamycin activ-
ated Akt (Figure 4D). Serum-starvation was more eff-
ective than rapamycin in preventing etoposide-induced 
senescence. This suggests that mTOR pathway is not 
the only pro-senescent pathway and that is why 
rapamycin was less effective than serum-starvation in 
preventing senescence. As an example, compared with 
rapamycin, serum starvation was a more potent inducer 




















































Effects of higher concentrations of etoposide 
 
We next investigated whether higher etoposide 
concentrations and durations of treatment convert 
quiescence into senescence. Like 0.5 µg/ml, 10 µg/ml 
etoposide did not inhibit mTOR (Figure 5A) and thus 
caused senescent morphology and loss of proliferative 
potential (Figure 5B, C). In WI-38t cells, rapamycin 
pretreatment partially preserved proliferative potential 
in both concentrations of etoposide (Figure 5B). Serum-
starvation was insignificantly effective probably due to 
its toxicity during a 6-day treatment. At the time of cell 
count (Figure 5B), WI-38t cells treated with etoposide 
alone  retained  senescent  morphology,  whereas           
co-treatment with rapamycin and serum starvation (no 








































RPE cells, which are more sensitive to etoposide, 
rapamycin and serum-starvation significantly preserved 
proliferative potential of cells treated with 0.5 µg/ml but 
not 10 µg/ml etoposide (Figure 5B). Still these co-
treatments abolished senescent morphology otherwise 
caused by 10 µg/ml etoposide (Figure 5C). 
 
Conversion from quiescence to senescence 
 
Using the schema depicted in Figure 6, we next investi- 
gated the effect of re-addition of serum to cells treated 
with DDD in serum-free medium without removal of 
the drug. In WI-38t cells, addition of serum caused 
phosphorylation of Akt, Erk and S6 and also induced 
cyclins D1 and E (Figure 7A). When stimulated with 
serum, these etoposide-arrested cells acquired senescent 
   













serum) were microphotographed.  morphology (Figure 7B). Thus senescence was 
characterized by activated mTOR-centric pathways and 
elevated cyclins D1 and E. Rapamycin prevented S6 
phosphorylation (downstream of mTOR), but not 
phosphorylation of Akt and Erk, which are upstream of 
mTOR. Simultaneously it diminished senescent morph-
ology, so that most cells remained lean (Figure 7B). 
Similar results were obtained when cells were blocked 
with doxorubicin (Figure 8). Re-addition of serum 
caused senescence instead of proliferation (Figure 8). 
Similarly, in etoposide- or doxorubicin- blocked RPE 
cells, serum stimulation caused activation of mTOR 

















   
 
 
Conversion between nutlin-induced quiescence and 
senescence in cancer cells 
 
Whereas nutlin-3a causes quiescence in WI-38t and 
RPE cells, it causes senescence in some cancer cell lines 
with high mTOR activity. For example, nutlin-3a did 
not block phosphorylation of S6 and caused senescence 
in Mel-10 cells. As we have shown, senescence was 
preventable by rapamycin [37]. The advantage of the 
nutlin-based model is that nutlin-3a does not cause 
DNA damage. Although serum-starvation did not cause 
genuine quiescence in cancer cells, serum starvation 
still prevented typical senescent morphology during 
treatment with nutlin-3a. Mel-10 cells remained slim, 
when were treated with nutlin-3a in serum-free 
medium.  The cells were beta-gal positive (Figure 
11A), because serum starvation alone may cause beta-
gal staining. Serum-starvation by itself did not 
decrease p-S6 by day 1 (Figure 11B), there was a 
noticeable decrease in phosphorylation of S6 in nutlin-
treated cells maintained in a serum-free medium 
(Figure 11B). Re-addition of serum converted lean 
morphology into typical senescent phenotype (Figure 
11C). In MCF-7 cells, nutlin-3a also induced senescent 
morphology (Figure 12A) and in agreement did not 
inhibit S6 phosphorylation (Figure 12C). However, 
non-proliferating senescent cells co-existed with still 
proliferating cells, which formed colonies with non-
senescent morphology. (Notably, higher concentration 
of nutlin-3a caused cell death, data not shown). Serum 
starvation slowed down proliferation of MCF-7 cells 
(Figure. 12B). Induction of p53 in serum-starved cells 
by nulin-3a caused rapid and massive  cell death 
(Figure 12A, lower panel). Nutlin-3a induced 
especially high levels of p53 in serum-starved cells 
(Fig 12C). This can explain both inhibition of p-S6 

































We also utilized rapamycin, which abrogated S6 
phosphorylation, while did not prevent p53 induction 
by nutlin-3a (Figure 12C). In rapamycin-pretreated 
MCF-7 cells, nutlin-3a did not cause morphological 
senescence (Figure 12A). In other words, senescence 
was converted into quiescence. Unlike senescent cells, 
quiescent cells were not morphologically distinct from 
proliferating cells. So after treatment with nutlin-3a 














etoposide  in  serum  free  medium.  24  h  after  serum 
stimulation,  cells  were  lysed  and  subjected  to  immuno‐
blotting as indicated (A).  4 days after serum stimulation 
cells were microphotographed (B). 
 proliferating and quiescent cells. Therefore, in order to 
link the morphology to the proliferative potential of 
arrested cells, we needed to selectively eliminate 
proliferating cells first. This task unexpectedly merged 
with our investigation of drug combinations that could 
protect cells with wt p53 from the toxicity of 
chemotherapy. Using this approach, we demonstrated 
that rapamycin converted nutlin-induced senescence 



































In this study we tested the idea that while causing 
senescence in proliferating cells, DNA damaging drugs 
and induced p53 will not cause senescence in quiescent 
cells. To this point we 1) induced quiescence prior to 
p53 induction and 2) used p53-inducing agents that 
could be washed out to observe whether treated cells 
would retain proliferative potential. Etoposide, which 
causes DNA damage, was used for normal cells and 
nutlin-3a, which induces p53 without DNA damage, 
was used for cancer cells. Both agents could be washed 






































drugs at concentrations that caused senescence in 
proliferating cells. When applied to serum-starved and 
rapamycin-treated cells, p53-inducing drugs did not 
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indicated  (A).  4  days  after  serum  stimulation  cells  were 
microphotographed (B).  












stimulation  cells  were  stained  for  beta‐Gal  and 
microphotographed. Bar – 50 micron. completely convert quiescence into senescence. Cells 
retained mostly quiescent morphology and some degree 
of proliferative potential, resuming proliferation in fresh 
(drug-free, serum-containing) medium. 
 
Although not causing senescence, induction of p53 in 
quiescent cells ‘locked’ the cell cycle. In quiescence 
caused by serum starvation, the cell cycle is inactive 
(due to low levels of cyclins) but not blocked.  In 
quiescent cells, induction of p53 blocks the cell cycle 
(in addition to its deactivation). Re-addition of serum to 
such blocked (locked) quiescent cells did not cause 
proliferation. Instead it caused senescence. This is in 
agreement with the notion that senescence is a form         









































is impossible [18,39].  
 
Thus, induction of p53 by different agents (including 
DNA damaging drugs) did not cause senescence in 
serum-starved and rapamycin-treated cells.  It is less 
clear whether DNA damaging agents induced identical 
DNA damage in all conditions. One potential problem 
is that DNA damaging drugs may induce a lesser DNA 
damage in quiescent cells. However, first, we utilized 
etoposide, which was reported to induce damage in all 
phases of the cell cycle [40-45]. Second, etoposide 
induced the same levels of p53 in proliferating, serum-
starved and rapamycin-treated cells. (Note: Although 
p53 could be induced independently from DNA 
























































































damage response such as gamma-H2AX is also not 
absolutely reliable marker because it may occur in the 
absence of DNA damage in senescent cells [46,47]). 
Therefore, direct measurement of DNA damage by 
comet assay is warranted. 0.5 µg/ml etoposide did not 
induce obvious comets both in control and serum-free 
conditions. 10 µg/ml etoposide induced comets in 
serum-starved cells (Supplemental Figure 1). We 
conclude that, in agreement with literature data, 
etoposide induces DNA damage in serum-starved cells 
(some of which may still cycling at the moment of 
etoposide treatment) but more detailed measurements 
are needed for quantitative results. Third, simultaneous 
serum-withdrawal and addition of doxorubicin also 
suppressed senescence and this effect cannot be 








































wal. Fourth, DNA damaging drugs were even more 
cytotoxic in serum free-medium, indicating damage. 
Thus, it is not that etoposide is less cytotoxic in serum-
free medium but rather that cells retain lean morphology 
and prolifertative potential (the ability to proliferate in 
fresh medium). At high concentrations, damaging 
agents and p53 can induce cell death rather than 
senescence in serum-starved cells. Yet, according to our 
preliminary data, if drugs are removed before death 
occurs, serum-restimulated survived cells can become 
senescent. TOR-independent latent senescence caused 
by high levels of DNA damage is an intriguing topic for 
further investigations. 
 
In conclusion, quiescence is characterized by inactive 
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quiescent cells has important physiological applications. 
Most cells of an adult organism are resting and there-
fore induction of p53 and DNA damage cannot cause 
senescence. In contrast, stimulation of GF-sensing 
mTOR-centric pathways can. ‘Locked’ quiescent cells 
represent post-mitotic cells in the organism, including 
muscle cells, adipocytes and neurons. While not trigger-
ing proliferation of such ‘locked’ cells, stimulation with 
growth factors, hormones and nutrients may cause their 
senescence. Conversion of quiescence to senescence is a 
model of physiological senescence. Locked (non-senes-
cent) cells undergo chronic over-stimulation and event-
ually senesce. At least in some in vitro cellular models, 
conversion of quiescence to senescence (physiological 
senescence) can be suppressed by rapamycin. 
 
MATERIALS AND METHODS 
 
Cell lines and reagents.  WI-38-Tert, WI-38 fibroblasts 
immortalized, and RPE, retinal pigment epithelial cells 
were described previously [18]. RPE cells were cultured 
in MEM with 10% FBS, WI-38-tert cells were cultured 
in low glucose DMEM with 10%FBS.  MEL-10, melan-
oma cell line, and MCF-7, breast cancer cell line, were 
cultured in DMEM (plus pyruvate) with 10% FBS.   
Rapamycin was obtained from LC Laboratories, MA, 
USA.  Nutlin-3a, etoposide and doxorubicin were from 
Sigma-Aldrich. 
 
Immunoblot analysis.  Whole cell lysates were prepared 
using boiling lysis buffer (1%SDS, 10 mM Tris.HCl, 
pH 74.).  Equal amounts of proteins were separated on 
10% or gradient polyacrylamide gels and transferred to 
nitrocellulose membranes.  The following antibodies 
were used: mouse anti-p53 (Ab-6) from Oncogene, 
mouse anti-p21 from BD Biosciences; rabbit anti-actin 
from Sigma-Aldrich; rabbit anti-phospho-S6 (Ser235/ 
236), mouse anti-S6, rabbit anti-phospho AKT, rabbit 
anti-LC3B, anti-phospho ERK from Cell Signaling; 
anti-cyclins D1 and E from Santa Cruz Biotechnology. 
Secondary goat anti-rabbit and goat anti-mouse HRP 
conjugated antibodies were from Chemicon and Bio-
Rad, respectively.  Signals were visualized using ECL 
chemilumenescence kit from Pierce. 
 
SA-β-Gal staining.  Beta-Gal staining was performed 
using Senescence-galactosidase staining kit (Cell 
Signaling Technology) according to manufacturer’s 
protocol.  Cells were incubated at 37
oC until beta-gal 
staining becomes visible.  Development of color was 
detected under light microscope.  
 
Neutral comet assay was performed according to 
manufacturer’s protocol. 
Proliferative potential was determined as described in 
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